Medication info

Naringenta Duo Tablet 2.5/850 milligrams

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Pharmgen Science Co., Ltd.
Appearance
Bilateral convex oval film-coated tablets of bright orange color
Packaging
60 tablets/Alu-Alu[60 tablets(10 tablets/Alu-AluX6)]
Approval status
Active

MFDS item code 202201809 · Approved 2022.05.03

Summary

Main use
Improves glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medication should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous history of antidiabetic drug treatment in whom adequate glycemic control cannot be achieved with monotherapy, the initial dose is 1 tablet of this medication 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medication 2.5/1000 mg twice daily. 2. Patients unable to achieve adequate glycemic control with metformin monotherapy: The initial dose is linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medication should start at their current doses of linagliptin and metformin. 4. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea: The initial dose of this medication should be considered to be linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's current metformin dose. When this medication is administered in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be needed to reduce the risk of hypoglycemia (see Precautions for Use, 3. Administration with Caution in the Following Patients). 5. Patients unable to achieve adequate glycemic control with combination therapy of insulin and metformin: The initial dose of this medication should be considered to be linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's current metformin dose. When this medication is administered in combination with insulin, a reduction in the insulin dose may be needed to reduce the risk of hypoglycemia (see Precautions for Use, 3. Administration with Caution in the Following Patients). No studies have been conducted to evaluate the safety and efficacy of switching to this medication in patients previously treated with another oral antihyperglycemic drug. Any change in the treatment regimen for type 2 diabetes may lead to changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other condition that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do Not Administer to the Following Patients).

Ingredients

Manufacturer
Pharmgen Science Co., Ltd.

Efficacy & effects

Improves glycemic control in type 2 diabetes mellitus

View approved original text

This drug is used to improve blood glucose control in patients with type 2 diabetes who require combined therapy of linagliptin and metformin, as an adjunct to dietary and exercise therapy.

How to take

Adult dose

The dose of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medication should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous history of antidiabetic drug treatment in whom adequate glycemic control cannot be achieved with monotherapy, the initial dose is 1 tablet of this medication 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medication 2.5/1000 mg twice daily. 2. Patients unable to achieve adequate glycemic control with metformin monotherapy: The initial dose is linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medication should start at their current doses of linagliptin and metformin. 4. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea: The initial dose of this medication should be considered to be linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's current metformin dose. When this medication is administered in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be needed to reduce the risk of hypoglycemia (see Precautions for Use, 3. Administration with Caution in the Following Patients). 5. Patients unable to achieve adequate glycemic control with combination therapy of insulin and metformin: The initial dose of this medication should be considered to be linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's current metformin dose. When this medication is administered in combination with insulin, a reduction in the insulin dose may be needed to reduce the risk of hypoglycemia (see Precautions for Use, 3. Administration with Caution in the Following Patients). No studies have been conducted to evaluate the safety and efficacy of switching to this medication in patients previously treated with another oral antihyperglycemic drug. Any change in the treatment regimen for type 2 diabetes may lead to changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other condition that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do Not Administer to the Following Patients).

Precautions

This drug may cause serious side effects, such as lactic acidosis, so caution is required. Lactic acidosis can occur when metformin hydrochloride, one of the main components of this drug, accumulates in the body, and delay in treatment may lead to death. Therefore, this drug should not be used in patients with severely impaired kidney function, acute illnesses, severe infections, or dehydration. Pregnant or lactating women, patients with type 1 diabetes, and patients with diabetic ketoacidosis should also not take this medication. During the use of this drug, symptoms of hypoglycemia should be monitored closely, especially when used in conjunction with other hypoglycemic agents such as insulin or sulfonylureas. Regular kidney function monitoring is required, and if abnormalities are found, consult a doctor immediately. Additionally, rare side effects such as acute pancreatitis or bullous pemphigoid may occur; therefore, if abdominal pain or skin blisters develop, notify medical personnel immediately. This drug may reduce vitamin B12 levels, so if taken long-term, monitoring of blood vitamin B12 concentrations is recommended. There may be interactions with other medications, especially when combined with drugs affecting kidney function or strong metabolic inducers or inhibitors. Care is necessary. If there is a plan for pregnancy or during pregnancy, consider insulin therapy instead of this drug, and it is recommended not to use it during breastfeeding. Elderly patients are prone to reduced kidney function, so dose adjustment and regular kidney function tests are necessary. The effect of this drug on driving or operating machinery is unclear, requiring caution. In cases of overdose, the risk of lactic acidosis increases, and immediate medical treatment is required, which may necessitate hemodialysis. When storing, keep out of reach of children and protect from moisture.

Side effects

  • Lactic acidosis
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • vitamin B12 deficiency and reduction
  • hypoglycemia
  • taste disturbance
  • cough
  • decreased appetite
Show 127 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • vesicular dermatitis
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • constipation
  • epigastric pain
  • enterocolitis
  • intestinal obstruction
  • gastroenteritis
  • shingles
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • speech disturbance
  • Alzheimer's disease
  • chest pain
  • fever
  • facial edema
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • viral upper respiratory infection
  • periodontitis
  • influenza
  • mediastinitis
  • pharyngitis
  • rhinitis
  • upper respiratory infection
  • dyspepsia
  • gastroesophageal reflux disease
  • gastritis
  • stomatitis
  • hypercholesterolemia
  • malnutrition
  • hyponatremia
  • drowsiness
  • chest discomfort
  • asthenia
  • epistaxis
  • oropharyngeal pain
  • voice disorders
  • nasal bleeding
  • male-pattern baldness
  • hyperhidrosis
  • hair loss
  • dermatitis
  • anxiety
  • insomnia
  • depression
  • hypertension
  • hearing loss
  • erectile dysfunction
  • goiter
  • anemia
  • dizziness
  • headache
  • drowsiness
  • osteoarthritis
  • limb pain
  • itching
  • confusion
  • nocturia
  • skin lesions
  • angina
  • acute myocardial infarction
  • unstable angina
  • stomatitis
  • fever
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • vitreous hemorrhage
  • facial edema
  • back pain
  • rotator cuff syndrome
  • diabetic neuropathy
  • subdural effusion
  • palpitations
  • corneal abrasion
  • falls
  • upper limb fracture

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect from air and humidity, and it is safe to store at room temperature between 1 and 30 degrees Celsius. Therefore, it is advisable to avoid too hot or too cold places and to keep it in a cool place out of direct sunlight.

Appearance and packaging

Appearance

Bilateral convex oval film-coated tablets of bright orange color

Package unit

60 tablets/Alu-Alu[60 tablets(10 tablets/Alu-AluX6)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.